Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivobotulinumtoxinA for lateral canthal lines
2014-005279-10Phase 3Unknown
- Sponsor
- Allergan
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lateral canthal rhytides and glabellar furrowing comparing MT10109L 24 U with Placebo (2 arms). Primary endpoint: Investigator and participant Day 30 responder rate. Status: unknown.
02
Drugs
nivobotulinumtoxinA
03
Conditions
lateral canthal rhytidesglabellar furrowing
Beyond the preview
Go deeper on 2014-005279-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005279-10.